NanoTomer
NanoTomer, Inc. is an innovative company founded in 2015, focused on targeted oncology therapies. Their mission is to improve patient outcomes through cutting-edge technologies and developing therapies that address unmet needs in oncology. They aim to become the technological standard in antibody/protein drug conjugates, providing industry leaders with valuable insights.
Industries
Nr. of Employees
small (1-50)
NanoTomer
200 Clarendon Street, Fl 17, Boston MA 02116
Products
MHA112
An antibody developed to bind a protein expressed in specialized venules associated with solid tumors and draining lymph nodes; intended to be conjugated to potent pharmaceutical payloads for treatment of primary tumors and metastases. Preclinical data have been generated in multiple solid tumor models in preparation for regulatory filing.
Protin101
A peptide fragment with tumor-targeting properties used as a basis for peptide–drug conjugates to deliver potent pharmaceuticals, and as a platform to enhance biological immunotherapies and support endogenous activation strategies for CAR-T.
MHA112
An antibody developed to bind a protein expressed in specialized venules associated with solid tumors and draining lymph nodes; intended to be conjugated to potent pharmaceutical payloads for treatment of primary tumors and metastases. Preclinical data have been generated in multiple solid tumor models in preparation for regulatory filing.
Protin101
A peptide fragment with tumor-targeting properties used as a basis for peptide–drug conjugates to deliver potent pharmaceuticals, and as a platform to enhance biological immunotherapies and support endogenous activation strategies for CAR-T.
Expertise Areas
- Targeted oncology therapeutics
- Antibody–drug conjugates
- Peptide–drug conjugates
- Preclinical cancer model development and testing
Key Technologies
- Antibody–drug conjugation
- Peptide–drug conjugation
- In vivo solid tumor models
- Targeted delivery to lymphatic-associated vasculature